Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome

急性肺损伤和急性呼吸窘迫综合征的治疗

• 批准号: 8429025
• 负责人: Rolf D Hubmayr
• 金额: $ 7.73万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-30 至 2012-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8429025
• 关键词: Acute; Acute Lung Injury; Adult; Adult Respiratory Distress Syndrome; Caring; Characteristics; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Consent Forms; Critical Illness; Edema; Electronics; Eligibility Determination; Enrollment; Ethics; Gender; Hypoxemia; Intensive Care Units; Lung Inflammation; Natural History; Outcome; Pathology; Patients; Pharmaceutical Preparations; Procedures; Protocols documentation; Publications; Research Personnel; Resources; Respiratory distress; Review Committee; Sampling; Syndrome; Teleconferences; Voting; base; data exchange; improved; meetings; member; mortality; patient population; prevent; protocol development

Acute lung injury (ALI) and its more severe form, adult respiratory distress (ARD), is a devastating clinical syndrome of sudden lung inflammation that results in severe edema and hypoxemia and requires care in the intensive care unit. Mortality is between 30-40% in controlled settings. To date, no single drug has proven effective for improving mortality in ALI/ARDS despite many large and small clinical trials. The objective of the Clinical Research Network (ARDSNet) is to develop and conduct clinical research trials to prevent, treat, and improve the outcome of patients with acute lung injury, acute respiratory distress syndrome, and possibly other related critical illnesses.

急性肺损伤（ALI）及其更严重的成人呼吸窘迫（ARD）是一种急性肺部炎症的破坏性临床综合征，导致严重的水肿和低氧血症，需要在重症监护病房中进行护理。在受控设置中，死亡率在30-40％之间。迄今为止，尽管进行了许多大型和小型临床试验，但尚无单一药物可有效提高ALI/ARD的死亡率。临床研究网络（ARDSNET）的目的是开发和进行临床研究试验，以防止，治疗和改善急性肺损伤，急性呼吸窘迫综合征以及可能其他相关危重疾病的患者的结果。